Veru Inc logo

Veru Inc

NEW
NAS:VERU (USA)  
$ 3 +0.065 (+2.21%) 10:08 PM EST
At Loss
P/B:
1.38
Market Cap:
$ 48.15M
Enterprise V:
$ 20.22M
Volume:
245.01K
Avg Vol (2M):
2.71M
Trade In:
Volume:
245.01K
At Loss
Avg Vol (2M):
2.71M

Business Description

Description
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Name Current Vs Industry Vs History
Cash-To-Debt
10.86
Equity-to-Asset
0.81
Debt-to-Equity
0.08
Debt-to-EBITDA
-0.1
Interest Coverage
N/A
N/A
N/A
Piotroski F-Score
2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
51.07
9-Day RSI
53.02
14-Day RSI
54.32
3-1 Month Momentum %
3.59
6-1 Month Momentum %
-3.75
12-1 Month Momentum %
-64.75

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
6.19
Quick Ratio
6.19
Cash Ratio
5.71

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-22.1
Shareholder Yield %
-37.15

GF Valueâ„¢

Veru Inc Filings

Filing Date Document Date Form
No Filing Data

Veru Inc Stock Events

Financials Calendars
Event Date Price ($)
Fourth quarter earnings conference call for 2026 2026-12-17 08:00 In 174 days
Annual report for 2026 2026-12-17 In 173 days
Fourth quarter earnings results for 2026 2026-12-17 In 173 days
Third quarter earnings conference call for 2026 2026-08-12 08:00 In 47 days
Third quarter earnings results for 2026 2026-08-12 In 46 days
Second quarter earnings conference call for 2026 2026-05-13 08:00 2.27 (+2.25%)
Second quarter earnings results for 2026 2026-05-13 2.27 (+2.25%)
General meeting for 2026 2026-03-12 09:00 2.53 (+3.27%)
Oppenheimer 36th Annual Healthcare Life Sciences Conference 2026-02-26 15:20 2.59 (-1.52%)
First quarter earnings conference call for 2026 2026-02-11 08:00 2.31 (-4.55%)
Show
Entries

Guru Commentaries on NAS:VERU

No articles.

Press Release

Subject Date
VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm 2023-12-14
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU 2023-11-19
VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU 2023-10-16
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate 2023-02-06
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU) 2023-02-03
VERU SHAREHOLDER ALERT: Jakubowitz Law Reminds Veru Shareholders of a Lead Plaintiff Deadline of February 6, 2023 2023-02-03
VERU LAWSUIT ALERT: Levi & Korsinsky Notifies Veru Inc. Investors of a Class Action Lawsuit and Upcoming Deadline 2023-02-02
VERU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm 2023-02-01
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Veru Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 6, 2023 - (NASDAQ: VERU) 2023-02-01
VERU INC. (NASDAQ: VERU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Veru Inc. (NASDAQ: VERU) 2023-02-01
10/Page

Articles on Veru Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1